New hope for treating sudden decline in down syndrome

This study is testing three different treatments for Down Syndrome Regression Disorder (DSRD), a serious condition where individuals with Down syndrome suddenly lose skills, stop speaking, and experience other severe symptoms. The trial will compare the safety and effectiveness of a sedative (lorazepam), an immune therapy (IVIG), and an immune-modulating pill (tofacitinib) in 66 adolescents and young adults. Researchers aim to find which treatment works best to control this devastating disorder and understand what causes it.